GlassScriptPhysician profile
Robert F Schaefer
NPI 1659481299
$3,209.30
in general payments reported to CMS, 2019-2025
30 companies · $949 in 2025
The $949 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $155 · 2021: $46.87 · 2022: $55.23 · 2023: $203 · 2024: $973 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,030 · Education: $77.08 · Debt Forgiveness: $17.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,030.45 |
| Education | $77.08 |
| Debt Forgiveness | $17.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $542.16 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $533.41 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $326.87 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $279.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $203.87 | 2019-2025 | Veozah |
| Amgen INC. | $140.02 | 2019-2025 | Otezla, Repatha, Evenity |
| Medtronic, INC. | $100.05 | 2023 | Corevalve Evolut R |
| Janssen Pharmaceuticals, INC | $98.72 | 2019-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.59 | 2024-2025 | Jardiance |
| Lundbeck LLC | $90.78 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.88 | 2025 | Caplyta |
| Pfizer INC. | $66.89 | 2019-2025 | |
| Allergan, INC. | $66.84 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $66.36 | 2025 | Rexulti |
| Amarin Pharma, INC. | $63.47 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $59.93 | 2019-2024 | |
| Valinor Pharma, LLC | $49.14 | 2024 | Movantik |
| Sunovion Pharmaceuticals INC. | $46.39 | 2019 | |
| Sumitomo Pharma America, INC. | $45.34 | 2025 | Gemtesa |
| Exact Sciences Corporation | $43.60 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $36.58 | 2019 | |
| Celgene Corporation | $32.42 | 2019 | |
| Abbott Laboratories | $24.66 | 2025 | Freestyle Libre 3 |
| Ge Healthcare | $19.50 | 2019 | |
| Glaxosmithkline, LLC. | $18.89 | 2024 | Arexvy |
| Baxter Healthcare | $17.50 | 2023 | |
| Sanofi-Aventis U.S. LLC | $15.90 | 2019 | |
| Electromed, INC. | $14.66 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.54 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.